[go: up one dir, main page]

NO20082075L - Anti-hyperkolesterolemiske forbindelser - Google Patents

Anti-hyperkolesterolemiske forbindelser

Info

Publication number
NO20082075L
NO20082075L NO20082075A NO20082075A NO20082075L NO 20082075 L NO20082075 L NO 20082075L NO 20082075 A NO20082075 A NO 20082075A NO 20082075 A NO20082075 A NO 20082075A NO 20082075 L NO20082075 L NO 20082075L
Authority
NO
Norway
Prior art keywords
compounds
cholesterol
hypercholesterolemic compounds
hypercholesterolemic
esters
Prior art date
Application number
NO20082075A
Other languages
English (en)
Inventor
Robert J Devita
Gregori J Moriello
Peter Lin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082075L publication Critical patent/NO20082075L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen tilveiebringer kolesterol-absorpsjonsinhibitorer med formel I og de farmasøytisk akseptable saltene og esterne derav. Forbindelsene er anvendbare til senking av plasmakolesterolnivåer, særlig LDL-kolesterol, og til behandling og forebyggelse av aterosklerose og aterosklerotiske sykdomstilfeller.
NO20082075A 2005-10-05 2008-05-02 Anti-hyperkolesterolemiske forbindelser NO20082075L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72378105P 2005-10-05 2005-10-05
PCT/US2006/038551 WO2007044318A2 (en) 2005-10-05 2006-09-29 Anti-hypercholesterolemic compounds

Publications (1)

Publication Number Publication Date
NO20082075L true NO20082075L (no) 2008-07-04

Family

ID=37845278

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082075A NO20082075L (no) 2005-10-05 2008-05-02 Anti-hyperkolesterolemiske forbindelser

Country Status (25)

Country Link
US (2) US20090137546A1 (no)
EP (1) EP1934175B1 (no)
JP (1) JP4879991B2 (no)
KR (1) KR20080050610A (no)
CN (1) CN101277930A (no)
AR (1) AR058068A1 (no)
AT (1) ATE488495T1 (no)
AU (1) AU2006302584B2 (no)
BR (1) BRPI0616834A2 (no)
CA (1) CA2624481C (no)
CR (1) CR9903A (no)
DE (1) DE602006018341D1 (no)
DO (1) DOP2006000211A (no)
EA (1) EA200801008A1 (no)
ES (1) ES2354460T3 (no)
GT (1) GT200600444A (no)
IL (1) IL190434A0 (no)
MA (1) MA30006B1 (no)
NO (1) NO20082075L (no)
PE (1) PE20070493A1 (no)
SV (1) SV2009002863A (no)
TN (1) TNSN08153A1 (no)
TW (1) TW200806623A (no)
WO (1) WO2007044318A2 (no)
ZA (1) ZA200802587B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ATE485267T1 (de) * 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008085300A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Anti-hypercholesterolemic compounds
US8029405B2 (en) 2008-05-30 2011-10-04 Hyundai Motor Company Gear train of automatic transmission for vehicles
WO2010056788A1 (en) * 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222532T2 (de) * 1991-07-23 1998-02-26 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU2943095A (en) * 1994-06-20 1996-01-15 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
ES2277890T3 (es) * 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2006086562A2 (en) * 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
EP1893222A4 (en) * 2005-06-15 2010-07-07 Merck Sharp & Dohme ANTI-HYPERCHOLESTERINAMIC COMPOUNDS
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2091915A1 (de) * 2006-11-02 2009-08-26 Sanofi-Aventis Deutschland GmbH Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften

Also Published As

Publication number Publication date
AU2006302584A1 (en) 2007-04-19
DE602006018341D1 (de) 2010-12-30
US20070078098A1 (en) 2007-04-05
AU2006302584B2 (en) 2011-10-13
CA2624481A1 (en) 2007-04-19
ATE488495T1 (de) 2010-12-15
SV2009002863A (es) 2009-02-19
PE20070493A1 (es) 2007-06-13
EP1934175B1 (en) 2010-11-17
KR20080050610A (ko) 2008-06-09
MA30006B1 (fr) 2008-12-01
DOP2006000211A (es) 2007-05-31
CN101277930A (zh) 2008-10-01
ES2354460T3 (es) 2011-03-15
EP1934175A2 (en) 2008-06-25
GT200600444A (es) 2007-05-04
ZA200802587B (en) 2009-06-24
EA200801008A1 (ru) 2009-02-27
CA2624481C (en) 2012-04-03
US7704988B2 (en) 2010-04-27
IL190434A0 (en) 2008-11-03
BRPI0616834A2 (pt) 2016-08-23
WO2007044318A3 (en) 2007-07-12
JP2009511475A (ja) 2009-03-19
CR9903A (es) 2008-07-29
AR058068A1 (es) 2008-01-23
JP4879991B2 (ja) 2012-02-22
TW200806623A (en) 2008-02-01
WO2007044318A2 (en) 2007-04-19
US20090137546A1 (en) 2009-05-28
TNSN08153A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
NO20082075L (no) Anti-hyperkolesterolemiske forbindelser
WO2005062824A8 (en) Anti-hypercholesterolemic compounds
WO2006138163A3 (en) Anti-hypercholesterolemic compounds
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
WO2007008541A3 (en) Cellular cholesterol absorption modifiers
IL187740A0 (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
IL187738A0 (en) New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
ZA200710604B (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2008137084A3 (en) Diazaquinolones that inhibit prolyl hydroxylase activity
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2008130600A3 (en) Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2005005453A3 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2008057336A3 (en) Heterocyclyl-substituted anti-hypercholesterolemic compounds
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
TNSN05306A1 (en) Substituted pyrrole derivatives.
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
ECSP088351A (es) Compuestos anti-hipercolesterolémicos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application